Orchestra BioMed (OBIO) said Wednesday it presented data showing that its investigational atrioventricular interval modulation, or AVIM, therapy improved echocardiographic markers of diastolic dysfunction, a key factor in heart failure among hypertensive patients.
The company said a retrospective analysis of its Moderato II study data showed that patients with diastolic dysfunction who received six months of AVIM therapy achieved lower office and ambulatory systolic blood pressure.
Echocardiographic changes were consistent with improved myocardial relaxation and diastolic compliance, the company added.
Price: 5.35, Change: -0.03, Percent Change: -0.56
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。